AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 529756: 4-[Dimethyl(pentadecyloxy)silyl]butanenitrile

Chemical compound data from PubChem database. IUPAC Name: 4-ethyl-6-methyl-1,2,3,5-tetrathiane. Molecular Formula: C5H10S4. Molecular Weight: 198.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525359: 2,3,5,6-Tetramethyl-4-thiaheptane

Chemical compound data from PubChem database. IUPAC Name: 2-methyl-3-(3-methylbutan-2-ylsulfanyl)butane. Molecular Formula: C10H22S. Molecular Weight: 174.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - TABLE 1T. Invasive pneumococcal disease, Age<5 years, Confirmed to Legionellosis

NNDSS - TABLE 1T. Invasive pneumococcal disease, age<5 years, Confirmed to Legionellosis - 2020. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2019 and 2020 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). 
§ Includes drug resistant and susceptible cases of Invasive Pneumococcal Disease.
Patent AT-E400317-T1: [Translated] TELEMETRY SYSTEM AND METHOD WITH VARIABLE PARAMETERS

A programmable telemetry circuit that may be programmed for high bandwidth, low Q; low bandwidth, high Q; or for other parameters. The programmable telemetry circuit may include a first coil; a high impedance path having a first node connected to a first node of the first coil; a low impedance path having a first node connected to the first node of the first coil; a capacitive path having a first node connected to a second node of the first coil; and an input path for coupling signals into the high impedance path, the low impedance path, and the capacitive path. The low impedance path may be connected in parallel with the high impedance path. The capacitive path may form a circuitous path with the high impedance path and the low impedance path. The programmable circuit may be programmed to select the high impedance path or the low impedance path.
Prevention Agenda 2019-2024 Tracking Indicators: State Trend Data

There are two datasets related to the State Level Prevention Agenda Tracking Indicators posted on this site. Each dataset consists of 99 state-level health tracking indicators and sub-indicators for the Prevention Agenda 2019-2024: New York State’s Health Improvement Plan.  A health tracking indicator is a metric through which progress on a certain area of health improvement can be assessed.  The indicators are organized by the Priority Area of the Prevention Agenda as well as the Focus Area under each Priority Area.  Priority areas include Prevent Chronic Disease; Promote a Healthy and Safe Environment; Promote Healthy Women, Infants and Children; Promote Well-Being and Prevent Mental and Substance Use Disorders; and Communicable Diseases. The data sets also include indicators about major cross-cutting health outcomes and indicators of health disparities, organized into Health Status and Reduce Health Disparities. The most recent year dataset includes the most recent state level data for all indicators. The trend dataset includes the most recent state level data and historical data, where available. Each dataset also includes the Prevention Agenda 2024 state objectives for the indicators. Sub-indicators are included in these datasets to measure health disparities among racial, ethnic, and socioeconomic groups and persons with disabilities.
Compound 530142: B-Aminoisobutyric acid, # 2

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-[bis(trimethylsilyl)amino]-2-methylpropanoate. Molecular Formula: C13H33NO2Si3. Molecular Weight: 319.66. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401578-T1: [Translated] METHOD FOR MEASURING SEMICONDUCTOR WAFERS USING AN OXIDE REINFORCED PROBE

A method of measuring at least one electrical property of a semiconductor wafer includes providing an elastically deformable and electrically conductive contact having an insulative oxide layer formed on an exterior surface thereof by a controlled oxidation process, such as, without limitation, thermal oxidation, anodic oxidation or deposition oxidation. A first electrical contact is formed between the oxide layer on the surface of the contact and a dielectric layer overlaying a top surface of the semiconductor wafer and a second electrical contact is formed with the semiconductor wafer. A CV type stimulus is applied between the first electrical contact and the second electrical contact. A response of the semiconductor wafer to the CV type stimulus is measured and at least one electrical property of the dielectric layer, the semiconductor wafer or both is determined from the response.
Compound 529086: 11H-Pyrido[2,1-b]quinazolin-11-one, 6,7,8,9-tetrahydro, 6-methyl

Chemical compound data from PubChem database. IUPAC Name: 6-methyl-6,7,8,9-tetrahydropyrido[2,1-b]quinazolin-11-one. Molecular Formula: C13H14N2O. Molecular Weight: 214.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Delayed union of femoral fractures in older rats:decreased gene expression

Background
          Fracture healing slows with age. While 6-week-old rats regain normal bone biomechanics at 4 weeks after fracture, one-year-old rats require more than 26 weeks. The possible role of altered mRNA gene expression in this delayed union was studied. Closed mid-shaft femoral fractures were induced followed by euthanasia at 0 time (unfractured) or at 1, 2, 4 or 6 weeks after fracture in 6-week-old and 12-15-month-old Sprague-Dawley female rats. mRNA levels were measured for osteocalcin, type I collagen α1, type II collagen, bone morphogenetic protein (BMP)-2, BMP-4 and the type IA BMP receptor.
        
        
          Results
          For all of the genes studied, the mRNA levels increased in both age groups to a peak at one to two weeks after fracture. All gene expression levels decreased to very low or undetectable levels at four and six weeks after fracture for both age groups. At four weeks after fracture, the younger rats were healed radiographically, but not the older rats.
        
        
          Conclusions
          (1) All genes studied were up-regulated by fracture in both age groups. Thus, the failure of the older rats to heal promptly was not due to the lack of expression of any of the studied genes. (2) The return of the mRNA gene expression to baseline values in the older rats prior to healing may contribute to their delayed union. (3) No genes were overly up-regulated in the older rats. The slower healing response of the older rats did not stimulate a negative-feedback increase in the mRNA expression of stimulatory cytokines.
Compound 526537: (7-hydroxy-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-1-yl)methyl 2-methylbut-2-enoate

Chemical compound data from PubChem database. IUPAC Name: (7-hydroxy-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-1-yl)methyl 2-methylbut-2-enoate. Molecular Formula: C13H21NO3. Molecular Weight: 239.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400456-T1: [Translated] VIBRATION DAMPER WITH ADJUSTABLE RESPONSE

A vibration isolator with an adjustable response. A vibration isolator for isolating a vibration source from a support structure include a base in engagement with the support structure and two supports connected to the base. At least one of the supports is slidably connected to the base. A flexible member having a generally elongate shape and an elongate length is supported by the two supports. The flexible member is attachable to the vibration source. Each support slidably engages the flexible member such that the flexible member can move relative to each support with the support that is slidably connected to the base being moveable along the elongate length of the flexible member.
Compound 530054: Hexadecane, 8-methyl-7-propyl

Chemical compound data from PubChem database. IUPAC Name: 8-methyl-7-propylhexadecane. Molecular Formula: C20H42. Molecular Weight: 282.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2010 CMHS Uniform Reporting System (URS) Output Tables for Republic of Marshall Islands

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2010. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 528895: Dipropylbarbituric acid M (oxo)

Chemical compound data from PubChem database. IUPAC Name: 5-(2-oxopropyl)-5-propyl-1,3-diazinane-2,4,6-trione. Molecular Formula: C10H14N2O4. Molecular Weight: 226.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Table 12. 2011-2012 NSDUH Alcohol Use and Binge Alcohol Use in the Past Month among Persons Aged 12 to 20, by State

Table 12. Alcohol Use and Binge Alcohol Use in the Past Month among Persons Aged 12 to 20, by State: Percentages, Annual Averages Based on 2011 and 2012 NSDUHs.  Results are provided by State.
Compound 527092: Methyl 2-hydroxy-6-methoxybenzoate

Chemical compound data from PubChem database. IUPAC Name: methyl 2-hydroxy-6-methoxybenzoate. Molecular Formula: C9H10O4. Molecular Weight: 182.17. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Comparison of 2006-2008 and 2008-2010 NSDUH Substate Region Estimates

This report compares 2006 to 2008 an d2008 to 2010 National Survey on Drug Use and Health (NSDUH) estimates among persons aged 12 or older by 362 substate regions within the 50 States and the District of Columbia. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE).
Autoimmune response to U1 small nuclear ribonucleoprotein (U1 snRNP) associated with cytomegalovirus infection

The induction of autoantibodies to U1 small nuclear ribonucleoprotein (U1 snRNP) complexes is not well understood. We present evidence that healthy individuals with cytomegalovirus (CMV) infection have an increased frequency and quantity of antibodies to ribonucleoprotein, directed primarily against the U1-70k protein. A significant association between the presence of antibodies to CMV and antibodies to the total RNP targeted by the immune response to the spliceosome (to both the Sm and RNP; Sm/RNP) was found for patients with systemic lupus erythematosus (SLE) but not those with mixed connective-tissue disease. CMV thus may play a role in inducing autoimmune responses in a subset of patients with systemic lupus erythematosus.
Service Area PUF - PY2016

The Service Area PUF (SA-PUF) is one of the seven files that make up the Marketplace PUF. The SA-PUF contains issuer-level data on the geographic coverage or service area (i.e., where the plan is offered) including state, county, and zip code. These data either originate from the Service Area template (i.e., template field), an Excel based form used by issuers to describe their plans in the QHP/SADP application process, or were generated by CCIIO for use in data processing (i.e., system-generated).
Supporting Evidence-Based Home Visitation Programs to Prevent Child Abuse and Neglect Project: Le Bonheur Community Outreach

Location: Shelby County, Tennessee

Home Visiting Program Selected: Nurse Family Partnership

Home Visiting Target Population: Shelby County residents who meet the overall criteria for Nurse-Family Partnerships: low-income, first-time mothers, 16-28 weeks pregnant. Nearly all participants will be African-American.

Project Overview:
Le Bonheur Community Outreach will implement a program called Shelby County Nurse Family Partnership Collaborative. The Tennessee Commission for Children and the director of the Le Bonheur Center for Children and Parents will co-chair the Nurse Family Partnership. The program's goals are designed to: 1) utilize the Nurse Family Partnership model to expand and enhance high quality home visitation programs proved to reduce child abuse and deliver other positive outcomes for children and families, 2) develop a replicable local infrastructure model to implement the Nurse Family Partnership, 3) establish a statewide partnership to support local expansion and enhancement of the Nurse Family Partnership and other evidence based home visitation programs in the state, and 4) provide guidance to the Nurse Family Partnership implementations around the country to more effectively serve clients with mental/behavioral health disorders. The proposed evaluation will included an implementation, outcomes and economic cost analysis.

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E40147-T1: [Translated] AQUEOUS ELECTROCOAT COATING AGENT AND ITS USE FOR COATING OBJECTS.

Chemical patent from PubChem database. Patent Number: AT-E40147-T1. Title: Novel Chemical Entity. Filing Date: 2003-02-03. Inventors: Smith, John A., Johnson, Mary B.. Abstract: The invention relates to a novel chemical entity with unique structural features and biological properties, suitable for development as a therapeutic ... IPC Classifications: C08G, C08K, A61K. This patent covers 13 claims related to 7 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
The Protective Factors Survey: A Tool for Prevention Programs to Measure Change

The Office on Child Abuse and Neglect seeks to build its capacity for evaluating the programs of its grantees for the prevention of child abuse and neglect. In this webinar, findings discussed in this survey include data that show caregivers high in protective factors have greater physical health.

Presenters: Casandra Firman, from the National Resource Center for CBCAP; Elenor Buffington, Karin Chang-Rios, Jackie Counts, and Heather Rasmussen from the Institute for Educational Research and Public Service, University of Kansas; and Toby Hyman and Jodi Tyson from the Nevada Department of Health and Human Services.

View Webinar (WMV - 69 MB)

Metadata-only record linking to the original dataset. Open original dataset below.
National Estimates of Drug-Related Emergency Department Visits, 2004-2011 - All Visits

Excel file with national estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits, covering 2004-2011. File includes all drug-related ED visits that are reportable to DAWN without regard for the reason for the visit or the specific drugs involved. It includes visits involving all forms of drug misuse or abuse plus visits resulting from adverse reaction, accidental ingestion, suicide attempts, and visits where patients were seeking detoxification services. These estimates are useful for looking at overall levels of drug involvement in ED visits.File includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol.  Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology.Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.
Table 18. Alcohol Dependence in the Past Year among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2008, 2009, and 2010 NSDUHs

This table presents the 2008 to 2010 National Survey on Drug Use and Health (NSDUH) estimates of past year alcohol dependence by those aged 12 or older by State and substate regions.
Selecting information technology for physicians' practices: a cross-sectional study

Background
          Many physicians are transitioning from paper to electronic formats for billing, scheduling, medical charts, communications, etc. The primary objective of this research was to identify the relationship (if any) between the software selection process and the office staff's perceptions of the software's impact on practice activities.
        
        
          Methods
          A telephone survey was conducted with office representatives of 407 physician practices in Oregon who had purchased information technology. The respondents, usually office managers, answered scripted questions about their selection process and their perceptions of the software after implementation.
        
        
          Results
          Multiple logistic regression revealed that software type, selection steps, and certain factors influencing the purchase were related to whether the respondents felt the software improved the scheduling and financial analysis practice activities. Specifically, practices that selected electronic medical record or practice management software, that made software comparisons, or that considered prior user testimony as important were more likely to have perceived improvements in the scheduling process than were other practices. Practices that considered value important, that did not consider compatibility important, that selected managed care software, that spent less than $10,000, or that provided learning time (most dramatic increase in odds ratio, 8.2) during implementation were more likely to perceive that the software had improved the financial analysis process than were other practices.
        
        
          Conclusion
          Perhaps one of the most important predictors of improvement was providing learning time during implementation, particularly when the software involves several practice activities. Despite this importance, less than half of the practices reported performing this step.
Losartan and diabetic nephropathy: commentaries on the RENAAL study

The RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) study is a multinational, double-blind, randomized, placebo controlled trial which was recently published. It was aimed to evaluate the effect of the angiotensin receptor blocker losartan in patients with diabetic nephropathy. The primary efficacy measure was the time to the first event of the composite end point of a doubling of serum creatinine, end-stage renal disease, or death. The conclusion was that losartan led to significant improvement in renal outcomes, that was beyond that attributable to blood pressure control in patients with type 2 diabetes and nephropathy.
        The perusal of the report raises concern, regarding to both the patient population as well as the outcome measures. At randomization, the placebo group included more patients with angina, myocardial infarction and lipid disorders than the losartan group. Information on glucose metabolism was disregarded, and data on antihyperglycemic therapy – which may have undesirable influences on cardiac performance – were not included in a multivariate analysis. In addition, only data on first hospitalization were reported, whilst information on total specific-cause hospitalizations was disregarded, thus potentially masking further unfavorable events. Furthermore, creatinine seems not to be a reliable surrogate end point. Based on its mechanism of action, losartan may possess favorable renoprotective properties. However, due to the methodological flaws and the incomplete data in the RENAAL study, the question of the effectiveness and safety of this drug in diabetic nephropathy remains yet unanswered.
Compound 528996: Nonacosane, 1,2-bis(methylthio)

Chemical compound data from PubChem database. IUPAC Name: 1,2-bis(methylsulfanyl)nonacosane. Molecular Formula: C31H64S2. Molecular Weight: 501.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399752-T1: [Translated] SOLID CATALYST COMPONENT AND CATALYST FOR OLEFIN POLYMERIZATION

Solid catalyst components and catalysts which comprise (a) a magnesium compound, (b) titanium tetra chloride, and (c) a phthalic acid diester or its derivative represented by a particular formula, can afford polymers of olefins in very high yield. Particularly, propylene polymers can be obtained in very high yield while retaining high stereoregularity. Moreover, they have high responsiveness to hydrogen. <IMAGE>